retatrutide triple agonist glp-1 gip glucagon phase 3 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type 2 diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide hits 28.3% weight loss

10.1038/onc.2013.369 Oncogene 157 ZhangY

Its crucial to recognise that when left untreated, pernicious anaemia can cause irreversible damage

In transgenic tobacco plants, when BnMKK1 gene has been introduced, it triggers ABA signaling and leads to drought sensitivity and water loss [158] whereas GhMKK5 gene reduces salt and other abiotic stresses [152]

Unlike NSAIDs, acetaminophen does not cause stomach irritation or increased bleeding risk, making it a preferred choice for individuals sensitive to gastrointestinal side effects

Moreover, 15% of trained healthcare professionals err while using inhalers, leading to suboptimal disease control and increased risk of exacerbations, hospitalizations, and death

Farber S, Diamond LK